We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subc... Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts. Show more
Ask ADVFN Intelligence (AI)
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -2.16 | -6.43048526347 | 33.59 | 35.2 | 29.1 | 677292 | 31.05051518 | CS |
| 4 | -9 | -22.2606975019 | 40.43 | 42.14 | 29.1 | 607158 | 34.31123912 | CS |
| 12 | -17.38 | -35.6074574882 | 48.81 | 50.9 | 29.1 | 531243 | 39.49369019 | CS |
| 26 | -16.1633 | -33.9612928711 | 47.5933 | 63.5 | 29.1 | 488255 | 46.11823728 | CS |
| 52 | -28.48 | -47.5379736271 | 59.91 | 72.29 | 29.1 | 528649 | 50.04885821 | CS |
| 156 | 9.93 | 46.1860465116 | 21.5 | 72.29 | 14.19 | 454639 | 42.63762264 | CS |
| 260 | 9.93 | 46.1860465116 | 21.5 | 72.29 | 14.19 | 454639 | 42.63762264 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
